Will Samsung’s US$110 Million Asia-Focused Deal Transform GRAIL’s (GRAL) Multi-Cancer Test Narrative

On June 25, 2026, GRAIL, Inc. closed a US$110 million equity financing with Samsung affiliates, including Samsung C&T Corporation, to support regulatory efforts for its Galleri multi-cancer early detection test and expand access internationally. By pairing fresh capital with a commercialization collaboration for Galleri in South Korea and potentially other Asian markets, the Samsung deal highlights external confidence in GRAIL’s technology and opens a pathway to broader geographic…Read More